In order to access this content you must be logged in and have a subscription to PL Intelligence.

PL Intelligence is a one-stop environment for time-conscious executives. Keeping you abreast of the latest developments in the life sciences industry, saving you time and money when you need it most.
Incara and Elan terminate option agreement
Amarin announces product partnership with Elan
DepoMed finalizes drug delivery agreement with Elan
Targeted Genetics forms partnership with Elan
Incara and Indevus out-license bucindolol to ARCA Discovery
Incara Pharmaceuticals Receives Approval for Phase II SBIR Grant for Cancer Research from NIH
Elan Announces Agreement with Vernalis Regarding North American Rights for Frova
Acorda Therapeutics Acquires Zanaflex® from Elan